SpyGlass Pharma appointed Anand Sundaram as Vice President, Head of Commercial, bringing over a decade of commercial launch experience in ophthalmic treatments to help advance their Drug Delivery Platform into Phase III trials.

Opthea, a clinical-stage biopharmaceutical company, announced that its CEO will present at the Oppenheimer Healthcare Life Sciences Conference. The company is developing a novel therapy, sozinibercept, for the treatment of wet age-related macular degeneration.

Opthea, a clinical-stage biopharmaceutical company, has appointed Kathy Connell, a commercial executive with business development expertise, to its Board of Directors. The appointment comes as Opthea prepares for the Phase 3 topline data readout of its wet AMD treatment, sozinibercept, in 2025.

Several ASX-listed companies saw their shares rise significantly on Monday, including Atturra, Bravura Solutions, Core Lithium, and Opthea. The gains were driven by various factors, such as acquisition agreements, positive guidance updates, and successful capital raises.

MVNOs World Congress 2024 recognized Optiva BSS Platform as Enterprise eSIM Solution of the Year